Back to article: Targeting the TGFβ pathway in uterine carcinosarcoma

FIGURE 2: TGFβ1 in UCS cell proliferation and cisplatin sensitivity.(A) CS-99 and (B) UMMT-ARK1 cells were grown in Matrigel and treated as represented, post 72h treatment cell viability was evaluated using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) and % cell viability compared to Vehicle (V) treated control is plotted. Data are mean ± SD of three independent experiments performed in triplicate. *, P< 0.05.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.